To Better Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Receive for Muscle Invasive Bladder Cancer (MIBC).
Patients' Treatment Preferences For Muscle Invasive Bladder Cancer Cancer: A Discrete Choice Experiment
1 other identifier
observational
60
1 country
1
Brief Summary
Through our study, we aim to understand the most important factors for patients when they decide on the type of treatment they receive for MIBC. Our study consists of a discrete choice experiment (DCE): a type of questionnaire used to elicit preferences in the absence of data. DCEs are frequently used in oncological research to elicit preferences from participants without directly asking them to state their preferred options. Participants undertaking our DCE questionnaire will presented with a series of alternative hypothetical scenarios containing several variables or "attributes" (5), each of which may have a number of variations or "levels".
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jul 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 2, 2022
CompletedFirst Posted
Study publicly available on registry
February 11, 2022
CompletedStudy Start
First participant enrolled
July 20, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 25, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2024
CompletedMarch 8, 2023
February 1, 2023
9 months
February 2, 2022
March 7, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Willingness to accept treatment attributes, and trade-offs between these, using a study-specific Discrete Choice Experiment (DCE) Questionnaire
Through study completion, an average of 1 year (Discrete Choice Experiment (DCE) Questionnaire). Trade-off from Marginal Rate of Substitution calculate as percentage points (0 to 100). ]
Study Arms (2)
Pilot study (n = 10)
10 participants will be recruited to complete the questionnaire (version 1). A research assistant will be present to help support them /answer any questions around the format. Readability and comprehension will be noted. Any changes (if needed) can be implemented to its format before the main data collection.
Discrete Choice Experiment Questionnaire (n = 50)
Discrete Choice Experiment (DCE) Patients
Interventions
Discrete Choice Experiment (DCE) Patients
First version of questionnaire (readability/comprehension check)
Eligibility Criteria
Men or women with diagnosed MIBC who are currently undergoing treatment or have previously completed treatment for MIBC
You may qualify if:
- Diagnosed with MIBC cancer and currently undergoing treatment or have previously completed treatment for MIBC
You may not qualify if:
- Any of other type of bladder cancer (unknown, metastatic, or non muscle invasive bladder cancer)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Simon Hughes
KCL/GSTTH
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 2, 2022
First Posted
February 11, 2022
Study Start
July 20, 2022
Primary Completion
April 25, 2023
Study Completion
January 1, 2024
Last Updated
March 8, 2023
Record last verified: 2023-02